Verteporfin

製品コードS1786 バッチS178609

化学情報

	Synonyms	CL 318952	Storage (From the date of receipt)	3 years-20°C （in the dark）powder
	化学式	C₄₁H₄₂N₄O₈
	分子量	718.79	CAS No.	129497-78-5
Solubility (25°C)*	体外	DMSO	100 mg/mL (139.12 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	ベルテポルフィン (Verteporfin (CL 318952)) は、TEAD-YAP 相互作用と YAP による肝肥大を阻害します。また、ポルフィリンに由来する強力な第 2 世代の光増感剤でもあります。ベルテポルフィンはオートファジー (autophagy) 阻害剤です。ベルテポルフィンは細胞増殖を阻害し、アポトーシス (apoptosis) を誘導します。
in vitro	Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. ^[1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. ^[2]
in vivo	Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. ^[1]

製品説明

ベルテポルフィン (Verteporfin (CL 318952)) は、TEAD-YAP 相互作用 と YAP による肝肥大を阻害します。また、ポルフィリンに由来する強力な第 2 世代の光増感剤でもあります。ベルテポルフィンはオートファジー (autophagy) 阻害剤です。ベルテポルフィンは細胞増殖を阻害し、アポトーシス (apoptosis) を誘導します。

in vitro

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. ^[1]

Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. ^[2]

in vivo

Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. ^[1]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Ki67+ and Sox10+ cells
	濃度	2 uM
	反応時間	72 h
	実験の流れ	Cells were treated with verteporfin (2 µM) for 72 hr for Brdu staining.
動物実験	動物モデル	Atoh1-Ptch mice
	投薬量	100 mg/kg
	投与方法	i.p.

参考

+ 展开

カスタマーフィードバック

: Data from [Data independently produced by J Exp Med, 2014, 211(11), 2249-63]

: Data from [Data independently produced by , , Theranostics, 2017, 7(5):1114-1132]

: Data from [Data independently produced by , , Cancer Lett, 2018, 423:36-46]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

GRK2 mediated degradation of SAV1 initiates hyperplasia of fibroblast-like synoviocytes in rheumatoid arthritis [ Acta Pharm Sin B, 2024, 14(3):1222-1240]	PubMed: 38486990
Piezo1 expression in chondrocytes controls endochondral ossification and osteoarthritis development [ Bone Res, 2024, 12(1):12]	PubMed: 38395992
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells [ Cancer Lett, 2024, 587:216692]	PubMed: 38342232
Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model [ J Pathol, 2024, 263(2):257-269]	PubMed: 38613194
Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model [ J Pathol, 2024, 10.1002/path.6282]	PubMed: 38613194
Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia [ Mol Oncol, 2024, 10.1002/1878-0261.13749]	PubMed: 39395205
MST1/2 regulates fibro/adipogenic progenitor fate decisions in skeletal muscle regeneration [ Stem Cell Reports, 2024, 19(4):501-514]	PubMed: 38552635
YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia [ iScience, 2024, 27(3):109125]	PubMed: 38420594
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells [ Cancer Sci, 2024, 10.1111/cas.16292]	PubMed: 39039802
IL-32 aggravates metabolic disturbance in human nucleus pulposus cells by activating FAT4-mediated Hippo/YAP signaling [ Int Immunopharmacol, 2024, 141:112966]	PubMed: 39178518

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。